GSK's Zejula (niraparib) Receives the US FDA's Approval as 1L Monotherapy Maintenance Treatment for Women with Advanced Ovarian Cancer Regardless of Biomarker Status
Shots:
- The approval is based on P-III PRIMA study assessing Zejula (300/200mg- qd) vs PBO in patients with newly diagnosed advanced ovarian cancer following complete or partial response to platinum-based CT regardless of biomarker status
- The P-III PRIMA study resulted in a 57% improvement in PFS in HRd population and a 38% reduction in the risk of disease progression in the overall population. The new individualized starting dose is based on the patient’s weight and/or platelet count; lower rates of hematological AEs were observed with the individualized dosing group
- Zejula (qd) is a PARP inhibitor- currently being evaluated in multiple pivotal studies and is an approved therapy in the US as monothx. for women with advanced OC beyond those with BRCAm disease in the 1L and recurrent maintenance treatment settings- as well as late-line primary treatment settings
Click here to read full press release/ article
Ref: GSK | Image: GSK
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com